Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight
January 01, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Propulsion of Small Lymphocytic Lymphoma Clinical Trial Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Domain | DelveInsight ...
Thérapeutique Knight annonce l’approbation de prix de Minjuvi® (tafasitamab) au Brésil
October 16, 2023 07:30 ET
|
Thérapeutique Knight inc.
MONTRÉAL, 16 oct. 2023 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé...
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
October 16, 2023 07:30 ET
|
Knight Therapeutics
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
Thérapeutique Knight annonce la soumission réglementaire du pémigatinib au Brésil
October 10, 2023 16:45 ET
|
Thérapeutique Knight inc.
MONTRÉAL, 10 oct. 2023 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé...
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
October 10, 2023 16:45 ET
|
Knight Therapeutics
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
IgA Nephropathy Market to Exhibit Growth at a Tremendous CAGR of ~20% by 2032 | DelveInsight
October 03, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- IgA Nephropathy Market to Exhibit Growth at a Tremendous CAGR of ~20% by 2032 | DelveInsight As potential therapies with novel mechanisms are being...
Antibodies Industry Poised for Remarkable Growth as Therapeutic Applications Expand Worldwide
September 15, 2023 09:43 ET
|
Research and Markets
Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The "Antibodies Market, By Drug Type, by Disease Indication By End User, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030"...
Global Leukemia Therapeutics Market Report 2023: Rising Prevalence of Leukemia is Driving Growth
May 08, 2023 05:33 ET
|
Research and Markets
Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Leukemia Therapeutics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 04, 2023 16:05 ET
|
Vir Biotechnology, Inc.
– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza – – Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company...
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
April 13, 2023 09:00 ET
|
Editas Medicine, Inc.
Emma Reeve to support Editas’ evolution in new role as Chair of the Board Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE)...